Skip to main content Accessibility help
×
Hostname: page-component-76fb5796d-x4r87 Total loading time: 0 Render date: 2024-04-27T09:42:50.505Z Has data issue: false hasContentIssue false

Chapter 37 - Peroxisomal diseases

from Section IV - Metabolic liver disease

Published online by Cambridge University Press:  05 March 2014

Paul A. Watkins
Affiliation:
Johns Hopkins University School of Medicine, Kennedy Krieger Institute, Baltimore, MD, USA
Kathleen B. Schwarz
Affiliation:
Johns Hopkins University School of Medicine; Pediatric Liver Center, Johns Hopkins Hospital, Baltimore, MD, USA
Frederick J. Suchy
Affiliation:
University of Colorado Medical Center
Ronald J. Sokol
Affiliation:
University of Colorado Medical Center
William F. Balistreri
Affiliation:
University of Cincinnati College of Medicine
Get access

Summary

General aspects of peroxisomes

Peroxisomes were first identified in renal proximal tubule cells by a Swedish graduate student in 1954. Initially called microbodies, these organelles were studied intensively by de Duve and coworkers. Because they contained enzymes that both produced (e.g. amino acid and urate oxidases) and degraded (e.g. catalase) hydrogen peroxide, de Duve proposed the name peroxisomes [1]. Microbodies found in some lower organisms and plants were named for the specialized functions that they carry out. For example, glyoxysomes of fungi and plants contain the five enzymes of the glyoxylate cycle and glycosomes house the enzymes of glycolysis in trypanosomes. While peroxisomes have been found in essentially all plant and animal cells with the exception of mature erythrocytes, they range in size from about 0.1μm (microperoxisomes of intestine and brain) up to 1.0μm (characteristic of hepatic and renal peroxisomes; range: 0.2–1.0μm) (Figure 37.1).

A single lipid bilayer comprises the peroxisomal membrane. The organelle’s matrix is finely granular, but microcrystalline cores of urate oxidase are present in the hepatic peroxisomes of some species (e.g. rats). No cores are found in human peroxisomes as humans lack urate oxidase. Unlike chloroplasts and mitochondria, peroxisomes contain no DNA although it has been speculated that all three organelles evolved from endosymbionts. Since the discovery of peroxisomes, numerous membrane proteins and matrix enzymes have been identified. Much research on peroxisomes has been fueled by the identification of patients whose cells lack either normal appearing organelles or one or more peroxisomal metabolic functions.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2014

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

de Duve, C, Baudhuin, P. Peroxisomes (microbodies and related particles). Physiol Rev 1966;46:323–357.CrossRefGoogle Scholar
Lazarow, PB, Black, V, Shio, H, et al. Zellweger syndrome: biochemical and morphological studies on two patients treated with clofibrate. Pediatric Res 1985;19:1356–1364.CrossRefGoogle ScholarPubMed
Ma, C, Agrawal, G, Subramani, S. Peroxisome assembly: matrix and membrane protein biogenesis. J Cell Biol 2011;193:7–16.CrossRefGoogle ScholarPubMed
Steinberg, SJ, Dodt, G, Raymond, GV et al. Peroxisome biogenesis disorders. Biochim Biophys Acta 2006;1763:1733–1748.CrossRefGoogle ScholarPubMed
Lai, DY. Rodent carcinogenicity of peroxisome proliferators and issues on human relevance. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2004;22:37–55.CrossRefGoogle ScholarPubMed
Varga, T, Czimmerer, Z, Nagy, L. PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochim Biophys Acta 2011;1812:1007–1022.CrossRefGoogle ScholarPubMed
Lazarow, PB, De Duve, C. A fatty acyl-CoA oxidizing system in rat liver peroxisomes; enhancement by clofibrate, a hypolipidemic drug. Proc Natl Acad Sci USA 1976;73:2043–2046.CrossRefGoogle ScholarPubMed
Kemp, S, Theodoulou, FL, Wanders, RJ. Mammalian peroxisomal ABC transporters: from endogenous substrates to pathology and clinical significance. Br J Pharmacol 2011;164:1753–1766.CrossRefGoogle ScholarPubMed
Dirkx, R, Meyhi, E, Asselberghs, S, et al. Beta-oxidation in hepatocyte cultures from mice with peroxisomal gene knockouts. Biochem Biophys Res Commun 2007;357:718–723.CrossRefGoogle ScholarPubMed
Wanders, RJ, Ferdinandusse, S, Brites, P. et al. Peroxisomes, lipid metabolism and lipotoxicity. Biochim Biophys Acta 2010;1801:272–280.CrossRefGoogle ScholarPubMed
Moore, SA, Hurt, E, Yoder, E, et al. Docosahexaenoic acid synthesis in human skin fibroblasts involves peroxisomal retroconversion of tetracosahexaenoic acid. J Lipid Res 1995;36:2433–2443.Google ScholarPubMed
Wanders, RJ, Komen, J, Ferdinandusse, S. Phytanic acid metabolism in health and disease. Biochim Biophys Acta 2011;1811:498–507.CrossRefGoogle ScholarPubMed
Watkins, PA. Very-long-chain acyl-CoA synthetases. J Biol Chem 2008;283:1773–1777.CrossRefGoogle ScholarPubMed
Lloyd, MD, Darley, DJ, Wierzbicki, AS. et al. Alpha-methylacyl-CoA racemase: an “obscure” metabolic enzyme takes centre stage. FEBS J 2008;275:1089–1102.CrossRefGoogle Scholar
Horrocks, LA, Sharma, M. Plasmalogens and O-alkyl glycerophospholipids. In Nawthorne, JN, Ansell, GB (eds.) Phospholipids. New Comprehensive Biochemistry. Amsterdam: Elsevier Biomedical, 1982, pp. 51–93.Google Scholar
Itzkovitz, B, Jiralerspong, S, Nimmo, G, et al. Functional characterization of novel mutations in GNPAT and AGPS, causing rhizomelic chondrodysplasia punctata (RCDP) types 2 and 3. Hum Mutat 2012;33:189–197.CrossRefGoogle ScholarPubMed
Keller, GA, Barton, MC, Shapiro, DJ, et al. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase is present in peroxisomes in normal rat liver cells. Proc Natl Acad Sci USA 1985;82:770–774.CrossRefGoogle ScholarPubMed
Kovacs, WJ, Olivier, LM, Krisans, SK. Central role of peroxisomes in isoprenoid biosynthesis. Prog Lipid Res 2002;41:369–391.CrossRefGoogle ScholarPubMed
Bader-Meunier, B, Florkin, B, Sibilia, J, et al. Mevalonate kinase deficiency: a survey of 50 patients. Pediatrics 2011;128:e152–e159.CrossRefGoogle ScholarPubMed
Williams, EL, Acquaviva, C, Amoroso, A, et al. Primary hyperoxaluria type 1: update and additional mutation analysis of the AGXT gene. Hum Mutat 2009;30:910–917.CrossRefGoogle ScholarPubMed
Kerckaert, I, Poll-The, BT, Wanders, RJA, et al. Hepatic peroxisomes in isolated hyperpipecolic acidaemia justify its classification as single peroxisomal enzyme deficiency. J Inherit Metab Dis 1999;22(Suppl 1):29.Google Scholar
Frerman, FE, Goodman, SI. Nuclear-encoded defects of the mitochondrial respiratory chain, including glutaric acidemia type II. In Scriver, CR, Beaudet, AL, Sly, WS, Valle, D (eds.) The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 1995, pp. 1611–1629.Google Scholar
Wanders, RJ, Waterham, HR. Peroxisomal disorders I: biochemistry and genetics of peroxisome biogenesis disorders. Clin Genet 2005;67:107–133.CrossRefGoogle ScholarPubMed
Peduto, A, Baumgartner, MR, Verhoeven, NM et al. Hyperpipecolic acidaemia: a diagnostic tool for peroxisomal disorders. Mol Genet Metab 2004;82:224–230.CrossRefGoogle ScholarPubMed
Yousef, IM, Perwaiz, S, Lamireau, T, et al. Urinary bile acid profile in children with inborn errors of bile acid metabolism and chronic cholestasis; Screening technique using Electrospray tandem mass-spectrometry (ES/MS/MS). Med Sci Monit 2003;9:MT21–31.Google Scholar
Hubbard, WC, Moser, AB, Tortorelli, S, et al. Combined liquid chromatography-tandem mass spectrometry as an analytical method for high throughput screening for X-linked adrenoleukodystrophy and other peroxisomal disorders: preliminary findings. Mol Genet Metab 2006;89:185–187.CrossRefGoogle ScholarPubMed
Ebberink, MS, Mooijer, PA, Gootjes, J, et al. Genetic classification and mutational spectrum of more than 600 patients with a Zellweger syndrome spectrum disorder. Hum Mutat 2010;32:59–69.CrossRefGoogle Scholar
Mohamed, S, El-Meleagy, E, Nasr, A, et al. A mutation in PEX19 causes a severe clinical phenotype in a patient with peroxisomal biogenesis disorder. Am J Med Genet A 2010;152A:2318–2321.CrossRefGoogle Scholar
Ferdinandusse, S, Overmars, H, Denis, S, et al. Plasma analysis of di- and trihydroxycholestanoic acid diastereoisomers in peroxisomal alpha-methylacyl-CoA racemase deficiency. J Lipid Res 2001;42:137–141.Google ScholarPubMed
Van Veldhoven, PP, Meyhi, E, Squires, RH, et al. Fibroblast studies documenting a case of peroxisomal 2-methylacyl-CoA racemase deficiency: possible link between racemase deficiency and malabsorption and vitamin K deficiency. Eur J Clin Invest 2001;31:714–722.CrossRefGoogle ScholarPubMed
Roth, KS. Peroxisomal disease: common ground for pediatrician, cell biologist, biochemist, pathologist, and neurologist. Clin Pediatr 1999;38:73–75.CrossRefGoogle ScholarPubMed
Bove, KE, Daugherty, CC, Tyson, W, et al. Bile acid synthetic defects and liver disease. Pediatr Dev Pathol 2000;3:1–16.CrossRefGoogle ScholarPubMed
Huybrechts, SJ, Van Veldhoven, PP, Hoffman, I, et al. Identification of a novel PEX14 mutation in Zellweger syndrome. J Med Genet 2008;45:376–383.CrossRefGoogle ScholarPubMed
Setchell, KD, Bragetti, P, Zimmer-Nechemias, L, et al. Oral bile acid treatment and the patient with Zellweger syndrome. Hepatology 1992;15:198–207.CrossRefGoogle ScholarPubMed
Keane, MH, Overmars, H, Wikander, TM, et al. Bile acid treatment alters hepatic disease and bile acid transport in peroxisome-deficient PEX2 Zellweger mice. Hepatology 2007;45:982–997.CrossRefGoogle ScholarPubMed
Arai, Y, Kitamura, Y, Hayashi, M, et al. Effect of dietary Lorenzo’s oil and docosahexaenoic acid treatment for Zellweger syndrome. Congenit Anom 2008;48:180–182.CrossRefGoogle ScholarPubMed
Dhawan, A, Mitry, RR, Hughes, RD. Hepatocyte transplantation for liver-based metabolic disorders. J Inherit Metab Dis 2006;29:431–435.CrossRefGoogle ScholarPubMed
Milliner, DS, Eickholt, JT, Bergstralh, EJ et al. Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. N Engl J Med 1994;331:1553–1558.CrossRefGoogle ScholarPubMed
Bergstralh, EJ, Monico, CG, Lieske, JC. et al. Transplantation outcomes in primary hyperoxaluria. Am J Transplant 2010;10:2493–2501.CrossRefGoogle ScholarPubMed
Cochat, P, Fargue, S, Harambat, J. Primary hyperoxaluria type 1: strategy for organ transplantation. Curr Opin Organ Transplant 2010;15:590–593.CrossRefGoogle ScholarPubMed
Heffron, TG, Rodriguez, J, Fasola, CG. et al. Successful outcome after early combined liver and en bloc-kidney transplant in an infant with primary hyperoxaluria type 1: a case report. Pediatr Transplant 2009;13:940–942.CrossRefGoogle Scholar
Malla, I, Lysy, PA, Godefroid, N, et al. Two-step transplantation for primary hyperoxaluria: cadaveric liver followed by living donor related kidney transplantation. Pediatr Transplant 2009;13:782–784.CrossRefGoogle ScholarPubMed
Rosenblatt, GS, Jenkins, RD, Barry, JM. Treatment of primary hyperoxaluria type 1 with sequential liver and kidney transplants from the same living donor. Urology 2006;68:427 e7–8.CrossRefGoogle ScholarPubMed
Nissel, R, Latta, K, Gagnadoux, MF, et al. Body growth after combined liver–kidney transplantation in children with primary hyperoxaluria type 1. Transplantation 2006;82:48–54.CrossRefGoogle ScholarPubMed
Bobrowski, AE, Langman, CB. Hyperoxaluria and systemic oxalosis: current therapy and future directions. Expert Opin Pharmacother 2006;7:1887–1896.CrossRefGoogle ScholarPubMed
Hoppe, B, Beck, BB, Milliner, DS. The primary hyperoxalurias. Kidney Int 2009;75:1264–1271.CrossRefGoogle ScholarPubMed
Hinson, DD, Rogers, ZR, Hoffmann, GF et al. Hematological abnormalities and cholestatic liver disease in two patients with mevalonate kinase deficiency. Am J Med Genet 1998;78:408–412.3.0.CO;2-H>CrossRefGoogle ScholarPubMed
Savolainen, K, Kotti, TJ, Schmitz, W, et al. A mouse model for {alpha}-methylacyl-CoA racemase deficiency: adjustment of bile acid synthesis and intolerance to dietary methyl-branched lipids. Hum Mol Genet 2004;13:955–965.CrossRefGoogle ScholarPubMed
Corzo, D, Gibson, W, Johnson, K, et al. Contiguous deletion of the X-Linked adrenoleukodystrophy gene (ABCD1) and DXS1357E: a novel neonatal phenotype similar to peroxisomal biogenesis disorders. Am J Hum Genet 2002;70:1520–1531.CrossRefGoogle ScholarPubMed
Mayatepek, E, Ferdinandusse, S, Meissner, T, et al. Analysis of cysteinyl leukotrienes and their metabolites in bile of patients with peroxisomal or mitochondrial beta-oxidation defects. Clin Chim Acta 2004;345:89–92.CrossRefGoogle ScholarPubMed
Baumgart, E, Vanhorebeek, I, Grabenbauer, M, et al. Mitochondrial alterations caused by defective peroxisomal biogenesis in a mouse model for Zellweger syndrome (Pex5 knockout mouse). Am J Pathol 2001;159:1477–1494.CrossRefGoogle Scholar
Baes, M, Van Veldhoven, PP. Generalised and conditional inactivation of Pex genes in mice. Biochim Biophys Acta 2006;1763:1785–1793.CrossRefGoogle ScholarPubMed
Reddy, JK. Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal beta-oxidation, PPARalpha, and steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2001;281:G1333–G1339.CrossRefGoogle ScholarPubMed
Janzen, N, Sander, S, Terhardt, M, et al. Rapid quantification of conjugated and unconjugated bile acids and C27 precursors in dried blood spots and small volumes of serum. J Lipid Res 2010;51:1591–1598.CrossRefGoogle ScholarPubMed
Maeda, K, Kimura, A, Yamato, Y, et al. Oral bile acid treatment in two Japanese patients with Zellweger syndrome. J Pediatr Gastroenterol Nutr 2002;35:227–230.CrossRefGoogle ScholarPubMed
Martinez, M, Vazquez, E, Garcia-Silva, MT, et al. Therapeutic effects of docosahexaenoic acid ethyl ester in patients with generalized peroxisomal disorders. Am J Clin Nutr 2000;71:376S-385S.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×